The Build Back Better bill is still bogged down by infighting among Democrats, and its numerous drug pricing provisions will likely undergo changes prior to any votes.
Although Congress was able to pass a $1.2 trillion bipartisan infrastructure package last week, the nearly $1.8 trillion Build Back [...] …
U.S. Senate Majority Leader Chuck Schumer (D-N.Y.) announced on Tuesday that congressional Democrats and the White House reached agreement on federal drug pricing legislation. | C-SPAN
Democratic lawmakers have come to an agreement for placing a limited drug price negotiation plan for the Medicare program into [...] …
Sectyr, a major provider of compliance platforms for 340B covered entities, has bought LicenseTrak, a system for managing license, contract, training, and other business tasks.
Sectyr, an established provider of compliance platforms for 340B covered entities, has acquired LicenseTrak, a system for managing license, contract, [...] …
California’s Medicaid (Medi-Cal) program remains on track to move its pharmacy benefit from managed care to fee-for-service early next year.
California’s Medicaid (Medi-Cal) program remains on track to move its pharmacy benefit from managed care to fee-for-service early next year, [...] …
If Congress changes hands during next year’s mid-term elections, expect a renewed effort to place significant restrictions on the 340B program, 340B Report Publisher and CEO Ted Slafsky predicts.
If Congress changes hands during next year’s mid-term elections, we can expect the 340B program to be back under the [...] …
The 340B orphan drug exclusion incentivizes manufacturers to get orphan designations for drugs approved to treat common diseases or conditions, a new government report says.
The ban on 340B discounts on orphan drugs for rural and free-standing cancer hospitals may give drug companies a powerful [...] …
A September 2019 protest in Cleveland against the Trump administration rule barring Title X-funded family clinics from providing abortion referrals.
Hundreds of family planning clinics that lost their Title X federal grants and 340B eligibility because they opposed a Trump-era [...] …
340B covered entities are bracing for a huge reimbursement cut due to start in January for Gilead pre-exposure prophylaxis (PrEP) medications.
340B covered entities are exploring buying health insurance for patients at risk of contracting HIV in response to a huge [...] …
Reps. Robin Kelly (D-Ill.), left, and Lisa Blunt Rochester (D-Del.), right, led the Sept. 24 letter urging CMS to end the nearly 30% cut in Medicare Part B drug payments to 340B hospitals.
Half of the Congressional Black Caucus (CBC) has asked Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure to [...] …
A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs.
A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs. …
*Sign up for news summaries and alerts from 340B Report
Copyright © 2025 340B Report, LLC
Reproduction of material from any 340B Report page without written permission is strictly prohibited.
